title: Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.
abstract: The protein encoded by the CHEK2 gene is involved in cellular repair of DNA damage. The truncating mutation, CHEK2*1100delC, seems to increase the risk for breast cancer. We investigated whether the CHEK2*1100delC mutation carrier status increases the risk for asynchronous contralateral breast cancer (CBC) and whether it interacts with radiation therapy (RT) or chemotherapy in regard to CBC risk. The germline mutation frequency was assessed in 708 women with CBC and 1395 women with unilateral breast cancer (UBC) in the Women's Environment, Cancer and Radiation Epidemiology (WECARE) Study whose first primary breast cancer was diagnosed before age 55 years and during 1985--1999. Seven women with CBC (1.0%) and 10 women with UBC (0.7%) were CHEK2*1100delC variant carriers (rate ratio (RR)=1.8, 95% confidence interval (CI)=0.6-5.4 for CBC vs UBC). Carriers who received RT for their first breast cancer, compared with non-carriers not treated with RT, had an RR of developing CBC of 2.6 (95% CI=0.8-8.7). We found no significant associations between the CHEK2*1100delC mutation and CBC overall or among those treated with RT. However, the sampling variability was such that modest increases in risk could not be excluded. Nonetheless, because this is a rare mutation, it is unlikely to explain a major fraction of CBC in the population.
authors.affiliation: Institute of Cancer Epidemiology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark. lene@cancer.dk
authors.forename: L
authors.initials: L
authors.lastname: Mellemkjaer
authors.forename: C
authors.initials: C
authors.lastname: Dahl
authors.forename: J H
authors.initials: JH
authors.lastname: Olsen
authors.forename: L
authors.initials: L
authors.lastname: Bertelsen
authors.forename: P
authors.initials: P
authors.lastname: Guldberg
authors.forename: J
authors.initials: J
authors.lastname: Christensen
authors.forename: A-L
authors.initials: AL
authors.lastname: Børresen-Dale
authors.forename: M
authors.initials: M
authors.lastname: Stovall
authors.forename: B
authors.initials: B
authors.lastname: Langholz
authors.forename: L
authors.initials: L
authors.lastname: Bernstein
authors.forename: C F
authors.initials: CF
authors.lastname: Lynch
authors.forename: K E
authors.initials: KE
authors.lastname: Malone
authors.forename: R W
authors.initials: RW
authors.lastname: Haile
authors.forename: M
authors.initials: M
authors.lastname: Andersson
authors.forename: D C
authors.initials: DC
authors.lastname: Thomas
authors.forename: P
authors.initials: P
authors.lastname: Concannon
authors.forename: M
authors.initials: M
authors.lastname: Capanu
authors.forename: J D
authors.initials: JD
authors.lastname: Boice
authors.forename: J L
authors.initials: JL
authors.lastname: Bernstein
mesh_terms: D001943:Breast Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000532:radiotherapy; D016022:Case-Control Studies; D064447:Checkpoint Kinase 2; D005260:Female; D005838:Genotype; D018095:Germ-Line Mutation / Q000235:genetics*; D006801:Humans; D008875:Middle Aged; D017346:Protein Serine-Threonine Kinases / Q000235:genetics* / Q000378:metabolism; D012307:Risk Factors; D018426:SEER Program
chemical_list: D064447:Checkpoint Kinase 2; C578634:CHEK2 protein, human; D017346:Protein Serine-Threonine Kinases